PubMed Health⌕ Search

PubMed · 12895169

An update on asthma management.

Abstract

Asthma remains a major cause of morbidity in the Australian community, despite enhanced strategies and interventions for achieving optimal outcomes. Although there is some evidence of over use of high doses of inhaled corticosteroids (ICS), there is also evidence for under use of ICS, despite long-term data demonstrating clear benefits of low doses. The present paper briefly discusses some of the issues that are pertinent to the development of sensitization and atopic disease, but focuses mainly on the current understanding of best clinical practice for adults with asthma and the optimal approach to management. A clear definition of asthma control and a systematic approach to down-titration to minimize ICS doses is crucial to achieving better outcomes. Patient self-management education and optimal therapy are the keys to achieving better outcomes, although uncertainty remains about recommendations for mild asthma, despite new data.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Jenkins. 2003. An update on asthma management.. https://doi.org/10.1046/j.1445-5994.2003.00433.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗